Biodexa hits key milestone for its type 1 diabetes candidate tolimidone, enrolls first patient in phase 2a study

Cardiff, united kingdom / access newswire / june 18, 2025 / when it comes to type 1 diabetes, treating this chronic condition can be difficult. after all, with this type of diabetes, the body's immune system attacks and destroys the beta cells that produce insulin.
BDRX Ratings Summary
BDRX Quant Ranking